Rotundic acid induces Cas3-MCF-7 cell apoptosis through the p53 pathway.

MCF-7 cells apoptosis p53 rotundic acid

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 16 01 2018
accepted: 13 04 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 19 1 2019
Statut: ppublish

Résumé

In the present study, the functions and mechanisms of rotundic acid (RA) underlying its induction of apoptosis in caspase-3-transfected MCF-7 human breast cancer cells (Cas3-MCF-7 cells) were investigated. RA induced apoptosis in Cas3-MCF-7 cells more efficiently compared with that in MCF-7 cells transfected with control plasmid. The results from an MTT assay demonstrated that RA effectively inhibited Cas3-MCF-7 cell viability in a dose-dependent manner and induced cell apoptosis via caspase-3 activity within 12 to 48 h. Western blotting and fluorescence-activated cell sorting demonstrated that RA initiated Cas3-MCF-7 cell apoptosis via p53 activation. The silencing of the p53 gene in the Cas3-MCF-7 cell line led to decreased RA-induced Cas3-MCF-7 cell caspase-3 activity and cell apoptosis. Collectively, the results of the present study indicate that caspase-3 serves a critical function in rotundic acid-induced apoptosis, and suggest that caspase-3 deficiency may contribute to the chemotherapy-resistance of breast cancer. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to chemotherapy. RA has the potential for development as a novel drug combined with reconstitution of caspase-3 gene therapy for the treatment of human breast cancer with caspase-3 deficiency.

Identifiants

pubmed: 30655810
doi: 10.3892/ol.2018.9616
pii: OL-0-0-9616
pmc: PMC6313092
doi:

Types de publication

Journal Article

Langues

eng

Pagination

630-637

Références

Phytother Res. 1999 Mar;13(2):151-6
pubmed: 10190191
Nature. 2000 Oct 12;407(6805):770-6
pubmed: 11048727
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Oncol. 2005 Jun;26(6):1675-80
pubmed: 15870885
Chem Pharm Bull (Tokyo). 2007 May;55(5):784-8
pubmed: 17473469
Am Fam Physician. 2008 Feb 1;77(3):311-9
pubmed: 18297955
J Cell Biochem. 2011 Jan;112(1):273-88
pubmed: 21080333
Molecules. 2012 Jan 31;17(2):1278-91
pubmed: 22293846
Cancer Treat Rev. 2012 Oct;38(6):760-6
pubmed: 22342104
PLoS One. 2012;7(2):e32267
pubmed: 22359675
J Cancer Res Clin Oncol. 2012 Jun;138(6):1045-55
pubmed: 22392074
Oncologist. 2013;18(2):134-40
pubmed: 23359433
J Biochem. 2013 Sep;154(3):237-48
pubmed: 23678008
Breast. 2013 Aug;22 Suppl 2:S27-9
pubmed: 24074787
Psychoneuroendocrinology. 2014 May;43:20-9
pubmed: 24703167
Clin Breast Cancer. 2014 Aug;14(4):228-34
pubmed: 24703985
Oncol Rep. 2015 May;33(5):2420-8
pubmed: 25812934
Medicine (Baltimore). 2015 Aug;94(32):e1359
pubmed: 26266392
J Cancer Res Ther. 2015 Jul-Sep;11(3):508-13
pubmed: 26458575
Biochem Biophys Res Commun. 2016 Mar 4;471(2):290-5
pubmed: 26850851
Z Naturforsch C. 2016;71(5-6):95-103
pubmed: 27166720
PLoS One. 2016 Jul 21;11(7):e0158963
pubmed: 27441372
Biomed Pharmacother. 2016 Dec;84:1906-1914
pubmed: 27863838
Biomed Pharmacother. 2017 Jan;85:202-208
pubmed: 27919736
Brain Res. 2017 Feb 15;1657:9-15
pubmed: 27923634
EBioMedicine. 2017 Mar;17:101-107
pubmed: 28219627
J Cell Mol Med. 2017 Dec;21(12):3506-3514
pubmed: 28767184
Cancers (Basel). 2018 May 19;10(5):null
pubmed: 29783721
Arch Toxicol. 2018 Aug;92(8):2645-2648
pubmed: 29947891
Phytochemistry. 1997 Jul;45(5):1073-8
pubmed: 9264607

Auteurs

Min-Lun Nan (ML)

Institute of Phytochemistry, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130000, P.R. China.

Xue Wang (X)

College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin 130042, P.R. China.

Hai-Jun Li (HJ)

Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

De-Hai Yu (DH)

Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Wen-Yi Sun (WY)

Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmaceutical Sciences in Jilin University, Changchun, Jilin 130021, P.R. China.

Hong-Mei Xu (HM)

Department of Obstetrics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Yu-Fang He (YF)

Institute of Phytochemistry, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130000, P.R. China.
Department of Pharmacy Administration, Changchun University of Chinese Medicine College of Management, Changchun, Jilin 130117, P.R. China.

Quan-Cheng Zhao (QC)

Institute of Phytochemistry, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130000, P.R. China.

Classifications MeSH